Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration

Next Previous
X
Search
Trial Profile

Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OLX 301A (Primary)
  • Indications Age-related macular degeneration
  • Focus First in man; Therapeutic Use
  • Sponsors OliX Pharmaceuticals

    • Most Recent Events

    • 10 Jan 2024 Planned number of patients changed from 48 to 42.
    • 29 Nov 2023 preliminary Results (n=15) presented in the OliX Pharmaceuticals Media Release.
    • 21 Sep 2023 Protocol amended to change dose in part A 1178.8 to 895.9 micro g/eye. Patient number changed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top